Impact of prandial plus basal vs basal insulin on glycemic variability in type 2 diabetic patients

Endocrine Practice

Volumn 15, Issue 4, 2009, Pages 343-348

  Hirsch, Irl B ^a,c   Yuan, Hongbo ^b   Campaigne, Barbara N ^b   Tan, Meng H ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN LISPRO; METFORMIN; PROTAMINE;

ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG DOSE COMPARISON; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; TREATMENT OUTCOME;

EID: 67649224999     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP08308.ORR     Document Type: Article

References (25)

1. Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care. 2006;29:1486-1490.
2. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutlege BN; DCCT/EDIC Research Group. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial--revisited. Diabetes. 2008;57:995-1001.
3. Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA. 2006;295:1707-1708.
4. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295:1681-1687.
5. Esposito K, Giugliano D, Nappo F, Marfella R; Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation. 2004;110:214-219.
6. Esposito K, Ciotola M, Carleo D, et al. Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes. J Clin Endocrinol Metab. 2008;93:1345-1350.
7. Monnier L, Colette C. Glycemic variability: should we and can we prevent it? Diabetes Care. 2008;31(Suppl 2):S150-S154.
8. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615-1625.
9. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes [erratum in Diabetes Care. 2006;49:2816-2818]. Diabetes Care. 2006;29:1963-1972.
10. International Diabetes Federation. Global Guideline for Type 2 Diabetes. Available at: http://www.idf.org/home/index.cfm?node=1457. Accessed February 08, 2008.
11. Ilag LL, Kerr L, Malone JK, Tan MH. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. Clin Ther. 2007;29:1254-1270.
12. Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH; Lispro Mixture-Glargine Study Group. Combined therapy with insulin lispro mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy [erratum in Clin Ther. 2005:27:1112]. Clin Ther. 2004;26:2034-2044.
13. Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre-Ferrante B. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabet Med. 2005;22:374-381.
14. Robbins DC, Beisswenger PJ, Ceriello A, et al. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24 week, randomized, open-label, parallel-group comparison. Clin Ther. 2007;29:2349-2364.
15. Service FJ, O'Brien PC, Rizza RA. Measurements of glucose control. Diabetes Care. 1987;10:225-237.
16. Wójcicki JM. "J"-index. A new proposition of the assessment of current glucose control in diabetic patients. Horm Metab Res. 1995;27:41-42.
17. Hirsch IB. Glycemic variability: it's not just about A1C anymore! Diabetes Technol Ther. 2005;7:780-783.
18. Grizzle JE. The two-period change-over design and its use in clinical trials. Biometrics. 1965;21:467-480.
19. Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications. 2005;19:178-181.
20. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)Hoxidase activation. Diabetes. 2003;52:2795-2804.
21. Jones SC, Saunders HJ, Qi W, Pollock CA. Intermittent high glucose enhances cell growth and collagen synthesis in cultured human tubulointerstitial cells. Diabetologia. 1999;42:1113-1119.
22. Schiekofer S, Andrassy M, Chen J, et al. Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs [erratum in Diabetes. 2003;52:1307]. Diabetes. 2003;52:621-633.
23. Service FJ, O'Brien PC. The relation of glycemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial [erratum in Diabetologia. 2002;45:936]. Diabetologia. 2001;44:1215-1220.
24. Kilpatrick ES, Rigby AS, Atkin SL. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care. 2008;28:2198-2202.
25. Tan MH, Le NA, Goldberg RB, et al. Post-prandial increase in hs CRP in patients with type 2 diabetes (T2D): comparison of lispro mid mixture (MM) plus metformin (met) with glargine (G) plus met [abstract]. Diabetologia. 2006;49 (Suppl 1):604.